Shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) ended Tuesday session in red amid volatile trading. The shares closed down -0.025 points or -4.08% at $0.585 with 1.36 million shares getting traded. Post opening the session at $0.61, the shares hit an intraday low of $0.57 and an intraday high of $0.62 and the price vacillated in this range throughout the day. The company has a market cap of $52.13 million and the numbers of outstanding shares have been calculated to be 85.12 million shares.
Pernix Therapeutics Holdings Inc (PTX) on Sept. 14, 2016 announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,421,200 (‘200 patent) and 9,433,619 (‘619 patent), covering important safety information related to dosing patients with Zohydro® ER with BeadTek™. These patents, in addition to recently issued U.S. Patent Numbers 9,265,760 (‘760 patent), 9,326,982 (‘982 patent), 9,333,201 (‘201 patent) and 9,339,499 (‘499 patent), are broadly directed to methods of dosing patients with mild or moderate hepatic impairment with hydrocodone. The ‘760, ‘982, ‘201, ‘499, ‘200, and ‘619 patents expire on July 25, 2033.
“The ‘200 and ‘619 patents, solely owned by Pernix, further strengthen our intellectual property portfolio covering Zohydro ER with BeadTek,” said John Sedor, Chairman and CEO of Pernix Therapeutics. “With the addition of these patents, Zohydro ER with BeadTek currently has nine patents listed in the FDA’s Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. In addition, several other patent applications related to this product are pending.”
Shares of Novartis AG (ADR) (NYSE:NVS) ended Tuesday session in green amid volatile trading. The shares closed up +0.15 points or 0.19% at $80.88 with 1.49 million shares getting traded. Post opening the session at $79.85, the shares hit an intraday low of $79.71 and an intraday high of $80.90 and the price vacillated in this range throughout the day. The company has a market cap of $211.73 billion and the numbers of outstanding shares have been calculated to be 2.38 billion shares.
Novartis AG (ADR) (NVS) on Sept. 23, 2016 announced that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.
Ilaris is the first and only FDA-approved biologic treatment for patients with Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF).1,2 All three conditions are part of a group of rare autoinflammatory diseases called Periodic Fever Syndromes, which are also referred to as Hereditary Periodic Fevers (HPF). The most common syndrome is FMF, which mainly affects people of Eastern Mediterranean ancestry. It affects 1 in 250 to 1 in 1,000 individuals in these populations, many of whom are children.
“We are grateful to the scientists, clinical trial investigators and all associates who worked tirelessly in support of patients to gain three simultaneous FDA approvals of ILARIS,” said Fabrice Chouraqui, President of Novartis Pharmaceuticals Corporation, “It is through their hard work that Novartis can offer a desperately needed new treatment option to the adults and children who suffer from these debilitating conditions and continue to serve the rare disease community.”